Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

REVEALED: William blair person | Rare Historical Photos

Hubble revisits the Crab Nebula after 25 years | Space photo of the day for March 24, 2026

NASA has released new Hubble telescope images of the Crab Nebula taken 25 years after the iconic observatory first gazed at the colorful cosmic crustacean.

Space

Old tech can learn new tricks. Colorful comparison photos of Crab Nebula wouldn’t have been possible with newer telescopes, NASA says

Images of the same colorful nebulae 25 years apart are a key example of why the Hubble Space Telescope's longevity matters

Digital Camera World

Tiny Biotech Terns Takes Aim At Novartis' Leukemia Blockbuster

Terns Pharmaceuticals, Inc. (NASDAQ:TERN) on Monday presented updated and expanded data from the ongoing CARDINAL trial of TERN-701 in previously treated chronic myeloid leukemia (CML) patients at the American Society of Hematology Annual Meeting and Exposition.

Benzinga

From analysis to the latest developments in health,
read the most diverse news in one place.

Ocular Therapeutix Stock Skyrockets On Faster FDA Path For Vision Drug

Ocular Therapeutix Inc. (NASDAQ:OCUL) stock surged on Monday after the company announced plans to accelerate the timeline for submitting a New Drug Application (NDA) for Axpaxli (OTX-TKI) in the treatment of wet age-related macular degeneration (wet AMD).

Benzinga

Medtronic Scores FDA Win As Hugo Surgical Robot Enters 230,000 Urology Procedure Market

On Wednesday, the U.S. Food and Drug Administration (FDA) cleared Medtronic Plc’s (NYSE:MDT) Hugo robotic-assisted surgery (RAS) system for use in urologic surgical procedures.

Benzinga

Simulations Plus Stock Climbs On Earnings Strength, Biotech Market Rebound

Simulations Plus Inc. (NASDAQ:SLP) shares climbed on Tuesday after the company reported better-than-expected fourth-quarter 2025 earnings and reaffirmed annual guidance.

Benzinga

Janux Therapeutics Stock Hits 52-Week Low After Trial Update

Janux Therapeutics Inc. (NASDAQ:JANX) stock hit a 52-week low on Tuesday after the company released updated interim data for its JANX007 Phase 1 program for metastatic castration-resistant prostate cancer (mCRPC).

Benzinga

Read news from The Economist, FT, and more,
with one subscription

Bayer Stroke Drug Hits Trial Goals, Analyst Sees Positive Data Readout From Bristol Myers' Milvexian After Failed Study

Bayer AG (OTC:BAYRY) released topline results from the Phase 3 OCEANIC-STROKE study, with its investigational, once daily, oral FXIa inhibitor asundexian.

Benzinga

Abbott's $21 Billion Exact Sciences Buyout Reshapes Cancer Diagnostics

Abbott Laboratories (NYSE:ABT) agreed on Thursday to acquire cancer screening company Exact Sciences Corp (NASDAQ:EXAS) for $105 per common share, representing a total equity value of approximately $21 billion and an estimated enterprise value of $23 billion.

Benzinga

This Undervalued Biotech Might Have Just Proven Its Star Drug's Staying Power

On Wednesday, Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) announced data from a post hoc analysis of the GALE extension study following five years of continuous treatment with Syfovre (pegcetacoplan injection) for geographic atrophy (GA) secondary to age-related macular degeneration (AMD).

Benzinga

Fiserv Stock Crashes 44% With CEO Exit, $30 Billion Wiped Out

Fiserv's stock plunges 44%, erasing £24B in value as growth slows, legal troubles rise, and leadership changes unsettle investors.

International Business Times UK

Incyte Delivers Robust Growth, But 2028 Patent Expiry Still Looms

Incyte Corporation's (NASDAQ:INCY) third-quarter revenue was $1.37 billion. The company beat the consensus of $1.26 billion.

Benzinga

Intuitive Surgical Q3 Results Ease Bear Market Concerns, Analyst Views 'Headwinds As Largely Noise'

Intuitive Surgical (NASDAQ:ISRG) reported revenue of $2.51 billion for the third quarter, up 23% year-over-year, beating analyst estimates of $2.40 billion.

Benzinga

Tesla Just Set a New Quarterly Delivery Record. Should You Buy TSLA Stock Here?

Tesla’s quarterly deliveries climb to a record 497,100 units in the third quarter. William Blair says it’s getting hard to stick with its neutral stance on TSLA stock.

Barchart

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

Bristol Myers Squibb Franchise Gains Momentum With Phase 3 Results In Multiple Myeloma Patients

Bristol Myers Squibb Co. (NYSE:BMY) on Tuesday announced results from the Phase 3 EXCALIBER-RRMM study evaluating iberdomide, an investigational cereblon E3 ligase modulator (CELMoD), combined with standard therapies (daratumumab + dexamethasone) in patients with relapsed or refractory multiple myeloma (RRMM).

Benzinga

Could This New Drug Be The Safer Way To Fight Obesity?

On Friday, Skye Bioscience, Inc. (NASDAQ:SKYE) announced the presentation of results from the Phase 1b study of nimacimab in subjects with metabolic-associated steatotic liver disease (MASLD) at the European Association for the Study of Diabetes (EASD) Annual Meeting.

Benzinga

PTC Therapeutics Could Challenge BioMarin For Metabolic Disorder Treatment

On Saturday, BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) released new Phase 3 PEGASUS study results on Saturday.

Benzinga

FDA Outlines Process To Speed Up Rare Disease Therapy Approvals

The U.S. Food and Drug Administration on Thursday introduced the Rare Disease Evidence Principles (RDEP) to provide greater speed and predictability in the review of therapies intended to treat rare diseases with very small patient populations.

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

Why Is Sanofi Stock Falling Thursday?

On Thursday, Sanofi SA (NASDAQ:SNY) stock tumbled after late-stage trial results for amlitelimab, its potential successor to blockbuster eczema drug Dupixent, failed to match investor expectations, raising fresh doubts about the company’s ability to sustain its dermatology franchise once patent protections expire.

Benzinga

NeoGenomics Gains 'Unexpected' Win As Court Rejects Natera Claims

On Friday, the District Court for the Middle District of North Carolina issued a ruling invalidating specific claims in two patents that Natera Inc. (NASDAQ:NTRA) asserted against NeoGenomics, Inc.'s (NASDAQ:NEO) v1.1 RaDaR test.

Benzinga

Telix Gets Second FDA Rejection For Kidney Cancer Drug

On Thursday, Telix Pharmaceuticals Limited (NASDAQ:TLX) received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) for the Biologics License Application (BLA) for TLX250-CDx (Zircaix, 89Zr-DFO girentuximab), an investigational PET2 agent for the diagnosis and characterization of renal masses as clear cell renal cell carcinoma (ccRCC).

Benzinga

Lung Disease-Focused Insmed 'Must-Own' Name For Investors

William Blair initiated coverage on Insmed Incorporated (NASDAQ:INSM), citing that the clinical and commercial execution of its drugs can significantly increase Insmed's valuation.

Benzinga

Vinay Prasad's Comeback To FDA Sparks Debate Over Regulatory Direction

In a stunning reversal, Dr. Vinay Prasad is returning to his role as director of the U.S. Food and Drug Administration’s (FDA) Center for Biologics Evaluation and Research (CBER), just days after his resignation.

Benzinga

Exact Sciences Dip A Chance To Buy As Freenome Deal Fortifies Future: Analyst

Exact Sciences Corp. (NYSE:EXAS) on Thursday reported a second-quarter 2025 EPS loss of 1 cent, up from a 9-cent loss a year ago, beating the analyst consensus loss estimate of 19 cents.

Benzinga

Elanco Animal Health Soars Past 52-Week High On Strong Sales, Raised Annual Outlook

Elanco Animal Health Incorporated (NYSE:ELAN) reported second-quarter 2025 results on Thursday, posting adjusted earnings per share of 26 cents, down 13% year over year.

1 2

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.